Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0042 dose-escalation study in AML, MDS, and CMML
NL-OMON60437Phase 2Suspended
- Sponsor
- Ellipses Pharma
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ep0042 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by Ellipses Pharma. Primary endpoints: Incidence of dose-limiting toxicities, Adverse events and serious adverse events and 1 more. Started Sep 2021; status: suspended.
02
Drugs
ep0042
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NL-OMON60437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60437.